No connection

Search Results

SLP vs TLSI

SLP
Simulations Plus, Inc.
BEARISH
Price
$14.37
Market Cap
$290.4M
Sector
Healthcare
AI Confidence
85%
TLSI
TriSalus Life Sciences, Inc.
BEARISH
Price
$4.60
Market Cap
$282.5M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
SLP
--
TLSI
--
Forward P/E
SLP
15.59
TLSI
-18.4
P/B Ratio
SLP
2.17
TLSI
-6.79
P/S Ratio
SLP
3.61
TLSI
6.26
EV/EBITDA
SLP
17.84
TLSI
-11.25

Profitability

Gross Margin
SLP
61.97%
TLSI
84.57%
Operating Margin
SLP
23.18%
TLSI
-24.77%
Profit Margin
SLP
-77.96%
TLSI
-86.88%
ROE
SLP
-38.84%
TLSI
--
ROA
SLP
3.81%
TLSI
-56.8%

Growth

Revenue Growth
SLP
8.3%
TLSI
59.8%
Earnings Growth
SLP
46.7%
TLSI
--

Financial Health

Debt/Equity
SLP
0.0
TLSI
--
Current Ratio
SLP
5.47
TLSI
2.8
Quick Ratio
SLP
5.26
TLSI
2.35

Dividends

Dividend Yield
SLP
--
TLSI
--
Payout Ratio
SLP
0.0%
TLSI
0.0%

AI Verdict

SLP BEARISH

Simulations Plus (SLP) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating a deteriorating financial trend. While the company maintains an exceptionally clean balance sheet with zero debt and high liquidity (Current Ratio 5.47), this is offset by a disastrous profit margin of -77.96% and a long-term price collapse of -76.6% over five years. The valuation is problematic, with a PEG ratio of 9.88 suggesting the stock is significantly overvalued relative to its growth. Despite optimistic analyst price targets, the deterministic data and bearish insider sentiment point to continued instability.

Strengths
Zero debt (Debt/Equity: 0.00)
Excellent liquidity (Current Ratio: 5.47)
Strong Gross Margins (61.97%)
Risks
Very weak Piotroski F-Score (2/9) indicating poor financial health trends
Extreme negative net profit margin (-77.96%)
Highly overvalued relative to growth (PEG Ratio: 9.88)
TLSI BEARISH

TLSI exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -6.79, indicating negative shareholders' equity. While the company shows strong top-line revenue growth of 59.80% and high gross margins, these are offset by a devastating profit margin of -86.88% and consistent earnings misses. The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider selling by the CEO and officers suggests a high-risk speculative profile. Overall, the deterministic health indicators signal a high probability of further capital erosion or dilution.

Strengths
Strong YoY revenue growth of 59.80%
High gross margin of 84.57% indicating strong product pricing power
Healthy short-term liquidity with a current ratio of 2.80
Risks
Negative shareholders' equity (P/B of -6.79) indicating insolvency risk
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Extreme negative profit margins (-86.88%)

Compare Another Pair

SLP vs TLSI: Head-to-Head Comparison

This page compares Simulations Plus, Inc. (SLP) and TriSalus Life Sciences, Inc. (TLSI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile